Arun K Rishi
Overview
Explore the profile of Arun K Rishi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
1776
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kommineni N, Nottingham E, Bagde A, Patel N, Rishi A, Dev S, et al.
Eur J Pharm Biopharm
. 2020 Nov;
158:172-184.
PMID: 33220423
Background: EGFR mutated NSCLCs have been shown to employ the use of CARP-1 in overriding the signaling inhibition of tyrosine kinase inhibitors (such as Osimertinib). CFM 4.17 is a CARP-1...
12.
Venkatesh J, Sekhar S, Cheriyan V, Muthu M, Meister P, Levi E, et al.
J Biol Chem
. 2020 Feb;
295(11):3532-3552.
PMID: 32024692
NF-κB is a pro-inflammatory transcription factor that critically regulates immune responses and other distinct cellular pathways. However, many NF-κB-mediated pathways for cell survival and apoptosis signaling in cancer remain to...
13.
Mondal A, Gebeyehu A, Miranda M, Bahadur D, Patel N, Ramakrishnan S, et al.
Sci Rep
. 2020 Jan;
10(1):1732.
PMID: 31992836
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
14.
Nottingham E, Sekar V, Mondal A, Safe S, Rishi A, Singh M
J Pharm Sci
. 2020 Jan;
109(6):1867-1882.
PMID: 31954111
We have investigated the effects of combination treatment involving ERL (erlotinib) with a glycyrrhetinic acid analog, CDODA-Me in overcoming ERL resistance, providing efforts to improve the oral bioavailability of this...
15.
Mondal A, Gebeyehu A, Miranda M, Bahadur D, Patel N, Ramakrishnan S, et al.
Sci Rep
. 2019 Dec;
9(1):19914.
PMID: 31882581
3D bioprinting improves orientation of in vitro tumor models by offering layer by layer positioning of cancer cells and cancer associated fibroblasts (CAFs) which can replicate tumor microenvironment. Aim of...
16.
Sekhar S, Venkatesh J, Cheriyan V, Muthu M, Levi E, Assad H, et al.
Cancers (Basel)
. 2019 Feb;
11(2).
PMID: 30769864
Cell Cycle and Apoptosis Regulatory Protein (CARP-1/CCAR1) is a peri-nuclear phosphoprotein that regulates apoptosis via chemotherapeutic Adriamycin (doxorubicin) and a novel class of CARP-1 functional mimetic (CFM) compounds. Although Adriamycin...
17.
Rossi N, Zenner Z, Rishi A, Levi E, Maliszewska-Scislo M
Am J Physiol Regul Integr Comp Physiol
. 2019 Jan;
316(2):R172-R185.
PMID: 30624974
The subfornical organ (SFO), a forebrain circumventricular organ that lies outside the blood-brain barrier, has been implicated in arterial pressure and baroreflex responses to angiotensin II (ANG II). We tested...
18.
Alsaab H, Sau S, Alzhrani R, Cheriyan V, Polin L, Vaishampayan U, et al.
Biomaterials
. 2018 Sep;
183:280-294.
PMID: 30179778
Drug resistance is one of the significant clinical burden in renal cell carcinoma (RCC). The development of drug resistance is attributed to many factors, including impairment of apoptosis, elevation of...
19.
Cheriyan V, Alsaab H, Sekhar S, Venkatesh J, Mondal A, Vhora I, et al.
Oncotarget
. 2018 Jul;
9(51):29680-29697.
PMID: 30038713
Non-small cell lung cancers (NSCLC) account for 85% of all lung cancers, and the epidermal growth factor receptor (EGFR) is highly expressed or activated in many NSCLC that permit use...
20.
Cheriyan V, Alsaab H, Sekhar S, Stieber C, Kesharwani P, Sau S, et al.
Oncotarget
. 2017 Dec;
8(62):104928-104945.
PMID: 29285223
Current treatments for Renal Cell Carcinoma (RCC) include a combination of surgery, targeted therapy, and immunotherapy. Emergence of resistant RCCs contributes to failure of drugs and poor prognosis, and thus...